240 related articles for article (PubMed ID: 3012508)
41. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Cotter MA; Cameron NE; Hohman TC
J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
[TBL] [Abstract][Full Text] [Related]
42. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
[TBL] [Abstract][Full Text] [Related]
43. [Risk factors for diabetic complications: Abnormality of polyol metabolism].
Hotta N
Nihon Rinsho; 2002 Oct; 60 Suppl 10():60-6. PubMed ID: 12430208
[No Abstract] [Full Text] [Related]
44. Polyol pathway and diabetic peripheral neuropathy.
Oates PJ
Int Rev Neurobiol; 2002; 50():325-92. PubMed ID: 12198816
[TBL] [Abstract][Full Text] [Related]
45. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Jacobson M; Sharma YR; Cotlier E; Hollander JD
Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors].
Cattalini M; Lerario AC
Rev Assoc Med Bras (1992); 1996; 42(2):109-14. PubMed ID: 9110460
[No Abstract] [Full Text] [Related]
47. [Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications].
Nishimura-Yabe C
Nihon Yakurigaku Zasshi; 1998 Mar; 111(3):137-45. PubMed ID: 9583077
[TBL] [Abstract][Full Text] [Related]
48. Medical therapy in the prevention of cataract.
Brown NA; Bron AJ
Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
[TBL] [Abstract][Full Text] [Related]
49. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
Nakamura J; Koh N; Sakakibara F; Hamada Y; Hara T; Sasaki H; Chaya S; Komori T; Nakashima E; Naruse K; Kato K; Takeuchi N; Kasuya Y; Hotta N
J Pharmacol Exp Ther; 1998 Dec; 287(3):897-902. PubMed ID: 9864270
[TBL] [Abstract][Full Text] [Related]
50. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition.
Hotta N
Nagoya J Med Sci; 1997 Nov; 60(3-4):89-100. PubMed ID: 9481088
[TBL] [Abstract][Full Text] [Related]
51. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia.
Segawa M; Hirata Y; Fujimori S; Okada K
Metabolism; 1988 May; 37(5):454-60. PubMed ID: 3285132
[TBL] [Abstract][Full Text] [Related]
52. The pharmacology of diabetic complications.
Altan VM
Curr Med Chem; 2003 Aug; 10(15):1317-27. PubMed ID: 12871132
[TBL] [Abstract][Full Text] [Related]
53. The sorbitol pathway and the complications of diabetes.
Gabbay KH
N Engl J Med; 1973 Apr; 288(16):831-6. PubMed ID: 4266466
[No Abstract] [Full Text] [Related]
54. The study of diabetic cataractogenesis in the intact rabbit lens by deuterium NMR spectroscopy.
Aguayo JB; McLennan IJ; Aguiar E; Cheng HM
Biochem Biophys Res Commun; 1987 Jan; 142(2):359-66. PubMed ID: 3101691
[TBL] [Abstract][Full Text] [Related]
55. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
[TBL] [Abstract][Full Text] [Related]
56. The role of aldose reductase inhibitors in diabetic complications: recent trends.
Kaul CL; Ramarao P
Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322
[TBL] [Abstract][Full Text] [Related]
57. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
[TBL] [Abstract][Full Text] [Related]
58. Diabetic retinopathy, nephropathy, and neuropathy with normal glucose tolerance.
Kabadi UM
Diabetes Care; 1986; 9(2):211-2. PubMed ID: 3698786
[No Abstract] [Full Text] [Related]
59. Aldose reductase in diabetic microvascular complications.
Chung SS; Chung SK
Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
[TBL] [Abstract][Full Text] [Related]
60. [Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy].
Kamijo M; Yagihashi S
Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1457-9. PubMed ID: 1837043
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
